Skip to main content
HairCited

Finasteride için Androgenetik Alopesi

A

129 çalışmaya (16 meta-analyses, 13 RCTs), toplam 18,623 katılımcıyla dayanmaktadır. 106/129 çalışma olumlu etkiler göstermektedir.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'ingredient\u003Dfinasteride\u0026condition\u003Dandrogenetic\u002Dalopecia'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

Sonuç

Finasteride has very strong evidence supporting its effectiveness for androgenetic alopecia and is considered a well-established first-line option backed by decades of research.

  • 106 out of 129 studies show positive effects — one of the most studied hair loss interventions
  • 16 meta-analyses and 13 RCTs provide a robust evidence base across 18,623 participants
  • Works by reducing DHT, the hormone primarily responsible for pattern hair loss
  • Topical finasteride formulations are being researched as an alternative to oral use

Key Study Findings

Review
Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments.
Dose: None vs: None Outcome: None Etki: None None

Popülasyon: women with androgenetic alopecia (female pattern hair loss)

non-randomized controlled trial n=60 16 weeks Open-label
Clinical Efficacy and Mechanisms of Microneedling Alone or Combined With Drugs in the Treatment of …
Dose: Mild group: microneedling alone (8 weeks); Moderate group: microneedling + 5% minoxidil (12 weeks); vs: Placebo Etki: All groups showed significant decrease in HLSS and increase in hair density post-treatment (p<0.001) p<0.001
randomized controlled trial n=45 16 weeks Open-label
Clinical and Trichoscopic Evaluations of Topical Finasteride 1%, Topical Spironolactone 5%, and Minoxidil 5% in …
Dose: Group A: topical finasteride 1% solution; Group B: topical spironolactone 5% solution; Group C: topi vs: Placebo Etki: Groups A and C showed significant improvement on Sinclair scale and trichoscopic hair density; Group None
Review
Male and female pattern hair loss.
Dose: None vs: Placebo Etki: None None
randomized controlled trial n=45 Open-label
Clinical efficacy of microneedle combined with 5% Minoxidil solution and finasteride in the treatment of …
Dose: Group A: 5% Minoxidil alone; Group B: 5% Minoxidil + Finasteride; Group C: Microneedling + 5% Minoxi vs: Placebo Etki: Hair density and hair shaft diameter increased in all groups; Group C superior to Group A in Norwood p<0.01

Key Statistics

206

Çalışmalar

24777

Katılımcılar

Positive

A

Derece

Referenced Papers

Aesthetic plastic surgery 2025 14 atıf
Anais brasileiros de … 2025 7 atıf
International journal of … 2025 5 atıf
Journal of cosmetic … 2025 3 atıf
European journal of … 2025 3 atıf
Australian prescriber 2025 2 atıf
Nature reviews. Disease … 2025
Annals of dermatology 2025
International journal of … 2024 39 atıf
Indian journal of … 2024 14 atıf
Dermatology (Basel, Switzerland) 2024 14 atıf
Journal of cosmetic … 2024 11 atıf
Journal of clinical … 2024 10 atıf
Facial plastic surgery … 2024 8 atıf
American family physician 2024 8 atıf
Photodermatology, photoimmunology & … 2024 8 atıf
International journal of … 2024 5 atıf
Drugs 2023 221 atıf
JAAD international 2023 80 atıf
Clinical, cosmetic and … 2023 58 atıf
American journal of … 2023 41 atıf
Anais brasileiros de … 2023 29 atıf
Journal der Deutschen … 2023 5 atıf
Journal of cosmetic … 2023 3 atıf
BMJ case reports 2023 2 atıf
Clinics in plastic … 2023 1 atıf
International journal of … 2023 1 atıf
The Journal of … 2022 65 atıf
Faculty reviews 2022 44 atıf
Dermatologic therapy 2022 41 atıf
Archivos espanoles de … 2022 9 atıf
Facial plastic surgery … 2022
Journal of cutaneous … 2021 44 atıf
Journal of the … 2021 42 atıf
Expert opinion on … 2020 147 atıf
Neurobiology of stress 2020 72 atıf
Facial plastic surgery … 2020 15 atıf
Dermatologic clinics 2020 15 atıf
Alternative therapies in … 2020 11 atıf
Journal of cosmetic … 2019 100 atıf
Assay and drug … 2019 19 atıf
The aging male … 2019 19 atıf
Indian journal of … 2018 79 atıf
Expert opinion on … 2018 38 atıf
Endocrine 2017 442 atıf
JAMA dermatology 2017 121 atıf
Current clinical pharmacology 2017 62 atıf
Actas dermo-sifiliograficas 2017 17 atıf
Deutsches Arzteblatt international 2016 99 atıf
The Cochrane database … 2016 18 atıf
Indian journal of … 2016 8 atıf
Current problems in … 2015 8 atıf
Der Internist 2015
Expert opinion on … 2014 57 atıf
Current opinion in … 2014 43 atıf
Giornale italiano di … 2014 8 atıf
Indian journal of … 2013 196 atıf
Dermatologic clinics 2013 78 atıf
Journal of cosmetic … 2013 62 atıf
Facial plastic surgery … 2013 16 atıf
International journal of … 2013
Expert opinion on … 2010 264 atıf
Current opinion in … 2009 54 atıf
Seminars in cutaneous … 2009 4 atıf
American family physician 2009
Nihon rinsho. Japanese … 2008 6 atıf
Endocrinology and metabolism … 2007 33 atıf
Acta dermatovenerologica Alpina, … 2005
Revue medicale de … 2004
Praxis 2003 28 atıf
American family physician 2003
Molecular and cellular … 2002
American journal of … 2000 18 atıf
Southern medical journal 2000
International journal of … 1999
American family physician 1999
Journal of the … 1999
Current pharmaceutical design 1999
Journal of cutaneous … 1999
Dermatologic clinics 1998 121 atıf
Annales de dermatologie … 1997

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Yaygın Kullanılan Dozajlar

hairloss:
1 mg/day oral

Üst sınır: 5 mg/day (BPH dose)

Araştırmalarda İncelenen Dozajlar

Dozaj Süre Etki N
None -- Neutral --
None -- Neutral --
Mild group: microneedling alone (8 weeks); Moderate group: microneedling + 5% minoxidil (12 weeks); 16 weeks Positive 60
Group A: topical finasteride 1% solution; Group B: topical spironolactone 5% solution; Group C: topi 16 weeks Positive 45
None -- Positive --
Group A: 5% Minoxidil alone; Group B: 5% Minoxidil + Finasteride; Group C: Microneedling + 5% Minoxi -- Positive 45
None -- Positive --
various across included studies (2015-2024) -- Positive --

En iyi alım zamanı: Once daily at the same time, with or without food

Safety & Side Effects

Bildirilen Yan Etkiler

  • Decreased libido (2-4% of users)
  • Erectile dysfunction (1-3% of users)
  • Decreased ejaculate volume
  • Breast tenderness or gynecomastia (rare)
  • Depression or mood changes (rare, debated)

Bilinen Etkileşimler

  • No significant drug-drug interactions identified
  • May affect PSA test results (reduces PSA by ~50%)
  • Contraindicated in pregnancy (Category X teratogen)

Tolere edilebilir üst alım: 5 mg/day (BPH dose)

Herhangi bir takviye kullanmaya başlamadan önce mutlaka sağlık uzmanınıza danışın.Herhangi bir takviye başlatmadan önce her zaman sağlık uzmanınıza danışın.

Frequently Asked Questions

Does Finasteride help with Androgenetik Alopesi?
Based on 206 studies with 24,777 participants, there is strong evidence from multiple clinical trials that Finasteride may support Androgenetik Alopesi management. Our evidence grade is A (Strong Evidence).
How much Finasteride should I take for Androgenetik Alopesi?
Studies have used various dosages. A commonly studied range is 1 mg/day oral. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Finasteride?
Reported side effects may include Decreased libido (2-4% of users), Erectile dysfunction (1-3% of users), Decreased ejaculate volume, Breast tenderness or gynecomastia (rare). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Finasteride and Androgenetik Alopesi?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 206 peer-reviewed studies with 24,777 total participants. The overall direction of effect is positive.

Related Evidence

FDA Sorumluluk Reddi: Bu ifadeler Gıda ve İlaç Dairesi (FDA) tarafından değerlendirilmemiştir. Bu web sitesindeki ürünler ve bilgiler herhangi bir hastalığı teşhis etmek, tedavi etmek, iyileştirmek veya önlemek amacıyla tasarlanmamıştır. Sunulan kanıt dereceleri, yayımlanmış hakemli araştırmalarımızın analizine dayanmaktadır ve tıbbi tavsiye niteliği taşımamaktadır. Herhangi bir takviye rejimine başlamadan önce her zaman sağlık uzmanınıza danışın.